Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070792 | 0.90 | ROCK2 (0.49) | ROCK2ROCK1MAPTPOLB | |
| SCHEMBL6070463 | 0.86 | IMPDH2 (0.54) | ROCK2ROCK1MAPTHPGD | |
| SCHEMBL6071406 | 0.84 | MAOB (0.48) | ROCK2MAPTNPC1POLB | |
| SCHEMBL6070594 | 0.82 | MAPK1 (0.54) | ROCK2HPGDNPC1 | |
| SCHEMBL5418918 | 0.81 | MAOB (0.58) | ROCK2ROCK1HPGDNPC1LMNA | |
| SCHEMBL6070912 | 0.81 | MAPK1 (0.51) | ROCK2ROCK1 | |
| SCHEMBL6071398 | 0.81 | MAPT (0.53) | MAPTHPGDNPC1POLB | |
| SCHEMBL6070656 | 0.80 | MAPT (0.48) | MAPTHPGDNPC1LMNAPOLB | |
| SCHEMBL6071038 | 0.79 | MAOB (0.39) | ROCK2MAPTHPGDNPC1LMNA | |
| SCHEMBL6071307 | 0.79 | MAOB (0.41) | HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | ROCK2 698/4885ROCK1 604/4885MAPT 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.